SPRC:NASDAQSciSparc Ltd. Analysis

SciSparc Ltd. (SPRC) trades at an extreme discount to peers, with a price‑to‑book of 0.055 and a trailing PE of 0.0025, while the biotech industry averages a PE of ~25. The stock’s price sits above its 20‑day SMA (5.36) and 50‑day SMA (4.86), and the MACD line is bullish at 1.12 above the signal line, suggesting short‑term upward momentum. However, the RSI of 66.7 indicates the stock is approaching overbought territory and the 30‑day volatility of 162% reflects a highly erratic price pattern. Volume is trending upward, but daily volume (~29k) is thin relative to the ~565k post‑split shares, creating liquidity concerns. Fundamentally, the company reports zero revenue growth, negative operating margins (‑5.7%), and a substantial cash burn with no cash on hand, resulting in a max drawdown of nearly 96%. The pipeline includes cannabinoid‑based therapies for Tourette’s, Alzheimer’s, autism, and chronic pain, but these remain early‑stage and subject to high regulatory risk. A recent 1‑for‑9 reverse share split reduces share count but does not alter the underlying financial weakness. The beta of 0.87 suggests modest market correlation, yet the combination of high volatility, negative cash flow, and speculative clinical outcomes makes the stock fundamentally fragile. Given the “Extreme Greed” market sentiment (fear‑greed index 91) the price may be temporarily buoyed, but the lack of cash, earnings, and clear path to profitability limits upside. In summary, while technicals hint at a modest short‑term rally, the company’s financial health and sector risks dominate the outlook.
Investors should treat SPRC as a high‑risk speculative play, with any upside heavily contingent on successful trial results and subsequent financing, which remain uncertain.